These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27733560)

  • 1. Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson's disease.
    Lipp MM; Batycky R; Moore J; Leinonen M; Freed MI
    Sci Transl Med; 2016 Oct; 8(360):360ra136. PubMed ID: 27733560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease.
    Safirstein BE; Ellenbogen A; Zhao P; Henney HR; Kegler-Ebo DM; Oh C
    Clin Ther; 2020 Jun; 42(6):1034-1046. PubMed ID: 32482490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease.
    Hauser RA; Isaacson SH; Ellenbogen A; Safirstein BE; Truong DD; Komjathy SF; Kegler-Ebo DM; Zhao P; Oh C
    Parkinsonism Relat Disord; 2019 Jul; 64():175-180. PubMed ID: 30992235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.
    LeWitt PA; Hauser RA; Pahwa R; Isaacson SH; Fernandez HH; Lew M; Saint-Hilaire M; Pourcher E; Lopez-Manzanares L; Waters C; Rudzínska M; Sedkov A; Batycky R; Oh C;
    Lancet Neurol; 2019 Feb; 18(2):145-154. PubMed ID: 30663606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic drug evaluation of CVT-301 for the treatment of Parkinson's disease.
    Stocchi F; Vacca L; Stirpe P; Torti M
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1189-1195. PubMed ID: 30479171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease.
    LeWitt PA; Pahwa R; Sedkov A; Corbin A; Batycky R; Murck H
    J Aerosol Med Pulm Drug Deliv; 2018 Jun; 31(3):155-161. PubMed ID: 29161531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease.
    LeWitt PA; Hauser RA; Grosset DG; Stocchi F; Saint-Hilaire MH; Ellenbogen A; Leinonen M; Hampson NB; DeFeo-Fraulini T; Freed MI; Kieburtz KD
    Mov Disord; 2016 Sep; 31(9):1356-65. PubMed ID: 27090868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa Inhalation Powder: A Review in Parkinson's Disease.
    Paik J
    Drugs; 2020 Jun; 80(8):821-828. PubMed ID: 32319076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study.
    Grosset DG; Dhall R; Gurevich T; Kassubek J; Poewe WH; Rascol O; Rudzinska M; Cormier J; Sedkov A; Oh C
    Parkinsonism Relat Disord; 2020 Feb; 71():4-10. PubMed ID: 31927343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial.
    Ondo WG; Shinawi L; Moore S
    Mov Disord; 2010 Dec; 25(16):2724-7. PubMed ID: 20925074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhaled levodopa for threatening impending OFF episodes in managing Parkinson's disease.
    Jost WH; Kulisevsky J; LeWitt PA
    J Neural Transm (Vienna); 2023 Jun; 130(6):821-826. PubMed ID: 37087697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa.
    Othman AA; Rosebraugh M; Chatamra K; Locke C; Dutta S
    J Parkinsons Dis; 2017; 7(2):275-278. PubMed ID: 28211816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets.
    Nyholm D; Askmark H; Gomes-Trolin C; Knutson T; Lennernäs H; Nyström C; Aquilonius SM
    Clin Neuropharmacol; 2003; 26(3):156-63. PubMed ID: 12782919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel by jejunal extension tube placement through percutaneous endoscopic gastrostomy for patients with advanced Parkinson's disease: a preliminary study.
    Zulli C; Sica M; De Micco R; Del Prete A; Amato MR; Tessitore A; Ferraro F; Esposito P
    Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2413-7. PubMed ID: 27338069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of Rytary
    Mittur A; Gupta S; Modi NB
    Clin Pharmacokinet; 2017 Sep; 56(9):999-1014. PubMed ID: 28236251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.
    Metman LV; Hoff J; Mouradian MM; Chase TN
    Mov Disord; 1994 Jul; 9(4):463-5. PubMed ID: 7969216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.
    Waters CH; Nausieda P; Dzyak L; Spiegel J; Rudzinska M; Silver DE; Tsurkalenko ES; Kell S; Hsu A; Khanna S; Gupta S
    CNS Drugs; 2015 Apr; 29(4):341-50. PubMed ID: 25895021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.
    Othman AA; Chatamra K; Mohamed ME; Dutta S; Benesh J; Yanagawa M; Nagai M
    Clin Pharmacokinet; 2015 Sep; 54(9):975-84. PubMed ID: 25875940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levodopa/carbidopa microtablets in Parkinson's disease: a study of pharmacokinetics and blinded motor assessment.
    Senek M; Aquilonius SM; Askmark H; Bergquist F; Constantinescu R; Ericsson A; Lycke S; Medvedev A; Memedi M; Ohlsson F; Spira J; Westin J; Nyholm D
    Eur J Clin Pharmacol; 2017 May; 73(5):563-571. PubMed ID: 28101657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.